FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3187581748> ?p ?o ?g. }

• W3187581748 endingPage "e1381" @default.
• W3187581748 startingPage "e1367" @default.
• W3187581748 abstract "Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease.In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders.Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases.Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment." @default.
• W3187581748 created "2021-08-16" @default.
• W3187581748 creator A5000520766 @default.
• W3187581748 creator A5003461044 @default.
• W3187581748 creator A5007665367 @default.
• W3187581748 creator A5011954252 @default.
• W3187581748 creator A5013829994 @default.
• W3187581748 creator A5015721189 @default.
• W3187581748 creator A5016234109 @default.
• W3187581748 creator A5016908006 @default.
• W3187581748 creator A5021324125 @default.
• W3187581748 creator A5023263132 @default.
• W3187581748 creator A5023925501 @default.
• W3187581748 creator A5025761608 @default.
• W3187581748 creator A5026604549 @default.
• W3187581748 creator A5029679895 @default.
• W3187581748 creator A5033285748 @default.
• W3187581748 creator A5034149246 @default.
• W3187581748 creator A5035227174 @default.
• W3187581748 creator A5038126368 @default.
• W3187581748 creator A5039406355 @default.
• W3187581748 creator A5041042684 @default.
• W3187581748 creator A5042577463 @default.
• W3187581748 creator A5046518405 @default.
• W3187581748 creator A5047138515 @default.
• W3187581748 creator A5047389830 @default.
• W3187581748 creator A5050690933 @default.
• W3187581748 creator A5051405149 @default.
• W3187581748 creator A5054405140 @default.
• W3187581748 creator A5055333491 @default.
• W3187581748 creator A5055780139 @default.
• W3187581748 creator A5056046035 @default.
• W3187581748 creator A5062496257 @default.
• W3187581748 creator A5068588668 @default.
• W3187581748 creator A5068749612 @default.
• W3187581748 creator A5070132070 @default.
• W3187581748 creator A5070451381 @default.
• W3187581748 creator A5072665088 @default.
• W3187581748 creator A5075292117 @default.
• W3187581748 creator A5075410889 @default.
• W3187581748 creator A5076156979 @default.
• W3187581748 creator A5077043739 @default.
• W3187581748 creator A5077914774 @default.
• W3187581748 creator A5078623289 @default.
• W3187581748 creator A5080357438 @default.
• W3187581748 creator A5081123756 @default.
• W3187581748 creator A5081544542 @default.
• W3187581748 creator A5082991473 @default.
• W3187581748 creator A5083474896 @default.
• W3187581748 creator A5083801943 @default.
• W3187581748 creator A5085451108 @default.
• W3187581748 creator A5086957329 @default.
• W3187581748 creator A5088112233 @default.
• W3187581748 creator A5089067055 @default.
• W3187581748 creator A5089086027 @default.
• W3187581748 creator A5091107365 @default.
• W3187581748 creator A5077451032 @default.
• W3187581748 date "2021-10-05" @default.
• W3187581748 modified "2023-10-17" @default.
• W3187581748 title "Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease" @default.
• W3187581748 cites W1941320055 @default.
• W3187581748 cites W1956043315 @default.
• W3187581748 cites W2002770279 @default.
• W3187581748 cites W2008134500 @default.
• W3187581748 cites W2015789019 @default.
• W3187581748 cites W2050923766 @default.
• W3187581748 cites W2075777499 @default.
• W3187581748 cites W2104829838 @default.
• W3187581748 cites W2120005990 @default.
• W3187581748 cites W2140978740 @default.
• W3187581748 cites W2152047920 @default.
• W3187581748 cites W2152487232 @default.
• W3187581748 cites W2200775787 @default.
• W3187581748 cites W2325451877 @default.
• W3187581748 cites W2431718082 @default.
• W3187581748 cites W2514674077 @default.
• W3187581748 cites W2523410404 @default.
• W3187581748 cites W2605154961 @default.
• W3187581748 cites W2614974832 @default.
• W3187581748 cites W2619579367 @default.
• W3187581748 cites W2623663856 @default.
• W3187581748 cites W2625168757 @default.
• W3187581748 cites W2736610570 @default.
• W3187581748 cites W2749718288 @default.
• W3187581748 cites W2753217510 @default.
• W3187581748 cites W2756731354 @default.
• W3187581748 cites W2766189188 @default.
• W3187581748 cites W2779417452 @default.
• W3187581748 cites W2786160501 @default.
• W3187581748 cites W2800919983 @default.
• W3187581748 cites W2803289465 @default.
• W3187581748 cites W2811135134 @default.
• W3187581748 cites W2884179398 @default.
• W3187581748 cites W2890518547 @default.
• W3187581748 cites W2898433344 @default.
• W3187581748 cites W2911813849 @default.
• W3187581748 cites W2913461658 @default.
• W3187581748 cites W2945563657 @default.

• next